Deferred registration: Fortrea code 780279
| ISRCTN | ISRCTN48262326 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN48262326 |
| Integrated Research Application System (IRAS) | 1013562 |
| Sponsor | Sanofi (France) |
| Funder | Sanofi France |
- Submission date
- 03/07/2026
- Registration date
- 03/07/2026
- Last edited
- 03/07/2026
- Recruitment status
- No longer recruiting
- Overall study status
- Deferred
- Condition category
- Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Contact information
Dr Benjamin Monaghan
Public, Scientific, Principal investigator
Public, Scientific, Principal investigator
Fortrea Clinical Research Unit (Drapers Yard)
Drapers Yard, Marshall St, Holbeck
Leeds
LS11 9EH
United Kingdom
| Phone | +44 (0) 113 301 3512 |
|---|---|
| benjamin.monaghan@fortrea.com |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Open (masking not used) |
| Control | Uncontrolled |
| Assignment | Crossover |
| Purpose | Pharmacokinetic |
| Scientific title | Deferred registration: Fortrea code 780279 [Full scientific title to be added on or before the deferral expiry date] |
| Study objectives | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Ethics approval(s) |
Approved 17/04/2026, London - Riverside REC (2nd Floor, 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; no telephone number provided; riverside.rec@hra.nhs.uk), ref: 26/LO/0071 |
| Health condition(s) or problem(s) studied | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Intervention | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Intervention type | Drug |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) | |
| Completion date | 07/10/2026 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 0 Years |
| Upper age limit | 1 Year |
| Sex | All |
| Target sample size at registration | 16 |
| Key inclusion criteria | The Health Research Authority has approved a deferral. Full details will be added to the trial record (including age limits) on or before the deferral expiry date |
| Key exclusion criteria | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Date of first enrolment | 28/08/2026 |
| Date of final enrolment | 28/08/2026 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Fortrea Clinical Research Unit (Drapers Yard)
Drapers Yard, Marshall St, Holbeck
Leeds
LS11 9EH
England
Leeds
LS11 9EH
England
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
03/07/2026: Trial's existence confirmed by London - Riverside REC.